Ireland
--:--IST
Recruiting Observational

Fibrinolysis Resistance in Infection and Trauma

NCT06680180 · tracked via the Priya Life Science Australia tracker
Sponsor
Anders Aneman
Phase
Observational
Started
2024-06-01
Last updated
2024-11-08

Condition(s) studied

Sepsis and Septic ShockTrauma

Investigational drug(s) / intervention(s)

Viscoelastometric assessment of fibrinolysis

Viscoelastometric assessment of fibrinolysis: Viscoelastometric assessment of whole blood fibrinolysis using supplemental tissue plasminogen activator (tPA) and other agents ex vivo to influence fibrinolysis capacity.

Study summary

Blood coagulation disorders are often seen in critically ill patients e.g. with severe infection or following extensive injury, that can lead to life threatening events as a result of excessive blood clot formation leading to organ failure. This study aims to use Viscoelastic Testing (VET) technology to detect patients at risk of excessive blood blot formation at the bedside, test new blood coagulation drugs, and guide life-saving use of blood modifying treatments.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
Accepted
Sepsis/Septic shock Inclusion Criteria: * Admission to ICU, needing at least one organ supportand principally for the management of clinically suspected Sepsis or Septic shock according to Spesis-3 criteria (including SARS-COV-2) * Expected to remain in ICU and survive beyond the day after tomorrow Sepsis Exclusion Criteria: * On oral anticoagulant/antiplatelet therapy * Not for full, active ICU support * Death is deemed inevitable within 24 hrs Trauma Inclusion Criteria: * Trauma is the principal diagnosis on ICU admission * Expected to remain in ICU and survive beyond the day after tomorrow * Receiving respiratory support at the time of ICU admission - high-flow nasal prongs, non-invasive or invasive ventilation * Already received, or considered at risk of needing a blood product transfusion within 24 hrs of injury Trauma Exclusion Criteria: * Nursing home resident * Unsurvivable head injury * Not for full, active ICU support * Death is deemed inevitable within 24 hrs

Primary outcome measure(s)

  • VET testing and analysis — From admission to ICU and at 24 hours, 48 hours, 5 days, 7 days, 10 days, and 15 days post ICU admission
    VET testing in whole blood will determine the kinetics and contribution of: i) both plasma and platelets to clot formation following the addition of tissue factor. ii) plasma clot formation only by adding tissue factor and platelet inhibitors. iii) tPA-induced fibrinolysis by adding tissue factor and tPA. The following test parameters will be used for analytical purposes: clotting time, clot amplitude at 10 min, maximum clot firmness, lysis time, maximum lysis. The platelet contribution to the clot will be calculated by subtracting (ii) from (i). An additional blood sample will be collected at the time of VET analysis for processing and storage for subsequent fibrinolysis protein analysis.
  • Laboratory evaluation of fibrinolytic profile — From admission to ICU and at 24 hours, 48 hours, 5 days, 7 days, 10 days, and 15 days post ICU admission
    We will evaluate the temporal changes in key fibrinolytic markers (i.e. plasminogen, antiplasmin, PAI-1 activity) and also changes in overall fibrinolytic capacity of patient plasma (i.e. how responsive plasma is to generate plasmin ex vivo) in relation to the VET testing. Commercial ELISAs will be used to determine plasminogen, alpha2 antiplasmin levels, PAI-1 and tPA activity; A novel tPA inducible plasmin-antiplasmin test will be used to evaluate plasmin generation; amidolytic assay will be used to determine plasmin activity.

Trial sites (4)

FacilityCityRegionStatus
The Canberra hospital (ICU) Canberra Australian Capital Territory Recruiting
Liverpool Hospital (ICU) Liverpool New South Wales Recruiting
Macquarie University Hospital (ICU) Macquarie New South Wales Recruiting
Royal North Shore Hospital (ICU) St Leonards New South Wales Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06680180 on ClinicalTrials.gov ↗ ← All trials in Australia